Skip to main content
. 2018 Dec 10;15(3):584–593. doi: 10.1080/21645515.2018.1538611

Figure 2.

Figure 2.

Potential impact* of PCV13 use in US adults aged ≥ 65 years51.

CAP = community-acquired pneumonia; US = United States; VE = vaccine effectiveness. *assumes 5% all-cause mortality each year and 100% vaccine uptake. A significant effect on all-cause mortality was not demonstrated in Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA).19